UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
Date of report (Date of earliest event reported): May 23, 2005
EPIX Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation)
|
000-21863 |
|
04-3030815 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
161 First Street, Cambridge, Massachusetts 02142
(Address of Principal Executive Offices) (Zip Code)
(617) 250-6000
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
On May 23, 2005, EPIX Pharmaceuticals, Inc. issued a press release today announcing that it has submitted a response to the approvable letter received from the U.S. Food and Drug Administration (FDA) in January 2005, for MS-325. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(c) The following exhibits are furnished with this report:
|
|
Description |
|
|
99.1 |
|
Press Release dated May 23, 2005. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
EPIX Pharmaceuticals, Inc. |
|
|
|
|
(Registrant) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: May 23, 2005 |
/s/ Peyton J. Marshall |
|
|
|
|
|
Peyton J. Marshall |
|
|
|
|
Senior Vice-President, |
|
|
|
|
Finance and Administration, |
|
|
|
|
Chief Financial Officer |
|
3